Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

MIND diet may shield stroke survivors from dementia

NCT ID NCT04337255

First seen May 07, 2026 · Last updated Jun 23, 2026 · Updated 5 times

Summary

This study tests whether following the MIND diet for 2 to 3 years can slow cognitive decline and reduce dementia risk in people aged 55 and older who have had an ischemic stroke. The MIND diet combines elements of the Mediterranean and DASH diets, with extra emphasis on leafy greens and berries. Researchers will compare changes in thinking skills and brain scans between those on the MIND diet and those receiving usual post-stroke care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STROKE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MIND diet (a hybrid of Mediterranean and DASH diets emphasizing green leafy vegetables and berries)

What this could lead to

If it works, this could show that a specific diet helps prevent dementia in people who have had a stroke.

What could go wrong

This is a behavioral intervention, not a drug, so results may be modest. The study is relatively small (250 people) and diet adherence can be challenging, which may weaken the findings.

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction dementia stroke disorder vascular dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.